(firstQuint)Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections.

 This is a phase I, open-label, single-dose study.

 The study aims to characterize the pharmacokinetics of CAZ-AVI and assess its safety and tolerability following a single IV dose given to hospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.

 This study will include 4 cohorts, each consisting of at least 8 evaluable pediatric patients, aged 3 months to <18 years, who are hospitalized with infections.

.

 Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections@highlight

To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in children from 3 months of age to <18 years.

